Fig. 4: MEKi/anti-CD40 Ab combination therapy increases CD8/Treg ratio and effector function of tumor-infiltrating T cells. | Nature Communications

Fig. 4: MEKi/anti-CD40 Ab combination therapy increases CD8/Treg ratio and effector function of tumor-infiltrating T cells.

From: Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Fig. 4

a Flow cytometric analysis of the impact of MEKi GDC-0623 and/or anti-CD40 Ab treatment on the T cell infiltrate in B16-OVA, MC-38, and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. Representative dot plots are shown. Cells were pre-gated on living, CD45+, CD3+, Thy-1.2+ cells. b–d Quantitation of CD8+ T cell to CD4+ CD25+ Foxp3+ regulatory T cell ratio, regulatory T cell frequencies among CD4+ T cells, and CD8+ T cell frequencies among living cells. #Two animals without Tregs. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). Mean ± s.e.m, n = 4. e TILs isolated from PDA30364 tumors were restimulated ex vivo with PMA/Ionomycin in presence of GolgiPlug and stained for intracellular IFNγ and TNFα. Mean ± s.e.m., n = 4. One-way ANOVA with post hoc Tukey’s test. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).

Back to article page